US Drug Recall Register
Class II · Moderate risk Terminated Initiated Mar 20, 2013 (13 years ago)

Itraconazole 1% eye ointment

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

What was recalled

Itraconazole 1% eye ointment, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907

Recalling firm
Clinical Specialties Compounding Pharmacy
Origin
GA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-648-2013

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Itraconazole recalls

See all
Class II · Moderate risk Terminated

Itraconazole Capsules

Reason Failed Dissolution Specifications

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-282-30 D-0333-2021
Class II · Moderate risk Terminated

Itraconazole USP

Reason CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

American Pharmaceutical Ingredients LLC NDC 58597-8133-3 D-0497-2018
Class II · Moderate risk Terminated

Itraconazole 0.2%/Mupirocin 0.2% Nasal Spray

Reason Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.

Well Care Compounding Pharmacy D-1027-2016
Class II · Moderate risk Terminated

Itraconazole active pharmaceutical ingredient packaged in varying…

Reason Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Attix Pharmaceuticals D-739-2015